Neue Therapieverfahren für die idiopathische Lungenfibrose am Horizont
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lambers C et al (2018) Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation. Sci Rep 8(1):1087
Roberts MJ et al (2021) Inhibition of the proliferation of human lung fibroblasts by prostacyclin receptor agonists is linked to a sustained cAMP signal in the nucleus. Front Pharmacol 12:669227
Kono M et al (2011) Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta 412(23–24):2211–2215
Yanagihara T et al (2022) Connective-tissue growth factor contributes to TGF-β1-induced lung fibrosis. Am J Respir Cell Mol Biol 66(3):260–270
Richeldi L et al (2020) Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med 8(1):25–33
Fibrogen announces topline results from phase 3 ZEPHYRUS‑1 study of pamrevlumab for the treatment of idiopathic pulmonary fibrosis. https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-topline-results-phase-3-zephyrus-1-study. Zugegriffen: 08.07.2023
Magnini D et al (2017) Idiopathic pulmonary fibrosis: molecular endotypes of fibrosis stratifying existing and emerging therapies. Respiration 93(6):379–395
Raghu G et al (2022) A phase IIb randomized clinical study of an anti-αvβ6 monoclonal antibody in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 206(9):1128–1139
Azam MA, Tripuraneni NS (2014) Selective phosphodiesterase 4B inhibitors: a review. Sci Pharm 82(3):453–481
Herrmann FE et al (2022) BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol 13:838449
Salgado-Polo F et al (2023) Autotaxin facilitates selective LPA receptor signaling. Cell Chem Biol 30(1):69–84
Ninou I, Magkrioti C, Aidinis V (2018) Autotaxin in pathophysiology and pulmonary fibrosis. Front Med (Lausanne) 5:180
Lei H et al (2020) Discovery of novel Indole-based allosteric highly potent ATX inhibitors with great in vivo efficacy in a mouse lung fibrosis model. J Med Chem 63(13):7326–7346
Maher TM et al (2018) Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med 6(8):627–635
Maher TM et al (2023) Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials. JAMA 329(18):1567–1578
Palmer SM et al (2018) Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis. Chest 154(5):1061–1069
Maher TM et al (2023) Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis. NEJM Evid. https://doi.org/10.1056/evidoa2300083
Kortekaas RK et al (2023) Interleukin-11 disrupts alveolar epithelial progenitor function. ERJ Open Res. https://doi.org/10.1183/23120541.00679-2022
Ng B et al (2019) Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aaw1237